AOD-9604

What it is

AOD-9604 (Anti-Obesity Drug 9604) is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment (residues 177–191) of human growth hormone, with a tyrosine residue added at the N-terminus. It was developed in the 1990s at Monash University in Australia by Frank Ng and colleagues and licensed to Metabolic Pharmaceuticals.

The peptide was originally developed on the hypothesis that the lipolytic effects of growth hormone could be separated from its mitogenic and diabetogenic effects by isolating the relevant active fragment. AOD-9604 represents this fragment plus the structural modification needed for synthesis. It received GRAS (Generally Recognized As Safe) status in the US for limited applications and is approved as a food supplement in some jurisdictions, but it has never received FDA pharmaceutical approval. In the US it is prescribed through licensed compounding pharmacies.

Mechanism of action

AOD-9604’s proposed mechanism centers on β3-adrenergic receptor signaling in adipose tissue. In animal studies, the peptide stimulates lipolysis (breakdown of stored triglycerides) and inhibits lipogenesis (formation of new triglycerides) without binding the growth hormone receptor and without raising insulin-like growth factor-1 (IGF-1). This receptor selectivity is the basis for its safety profile compared to recombinant human growth hormone.

Specific mechanisms documented in preclinical models:

• Increased β3-adrenergic receptor expression and downstream cAMP signaling in adipocytes
• Enhanced fatty acid oxidation in muscle tissue
• Improved peripheral insulin sensitivity in some animal models
• No detectable effect on growth hormone receptor activation, IGF-1 levels, or insulin-glucose dynamics in standard testing

The half-life is short — approximately 30 minutes after subcutaneous administration — which has implications for dosing frequency and explains why daily injection is the standard approach.

Research findings

The preclinical literature on AOD-9604 is solid. Multiple animal studies in rodent obesity models demonstrate consistent reductions in body fat without effects on lean mass and without elevations in IGF-1 or insulin resistance markers.

The largest human trial was a 2007 phase IIb study by Heffernan and colleagues (Obesity) involving 534 obese subjects randomized to placebo or one of four AOD-9604 doses (1, 5, 10, or 30 mg daily oral) for 12 weeks. Results were modest: mean weight loss in active arms was 1.4–2.3 kg vs. 0.8 kg with placebo. The effect size was statistically significant at the 1 mg dose but did not show clear dose-response and did not approach the magnitude of effect seen with subsequently developed therapies.

The 2007 study used oral administration, which has poor bioavailability for peptides. Subcutaneous administration — the route used in clinical compounded use — has not been evaluated in large randomized trials in humans. Practitioner experience suggests modest fat loss benefit when used as part of broader metabolic protocols, particularly when GH-axis-related side effects of stronger interventions need to be avoided.

How we use it at The Tide

We prescribe AOD-9604 selectively. Typical use cases:

• As an adjunct in metabolic protocols where a patient cannot tolerate or has contraindications to GLP-1 therapy
• For patients who have plateaued on GLP-1 monotherapy and want to add a low-side-effect tool
• For patients with localized stubborn fat (often abdominal) who have already optimized weight through other means

Standard cycle: 300 mcg subcutaneously once daily, typically in the morning before food, for 8–12 weeks. We monitor weight, waist circumference, and patient-reported outcomes monthly. No specific lab monitoring is required given the absence of GH-axis effects, though we maintain our standard metabolic panel cadence.

What we tell patients: we present AOD-9604 honestly as a low-side-effect adjunct with modest published evidence. We do not present it as a primary weight loss agent. Patients seeking maximum weight loss benefit are better served by GLP-1-class therapies.

Side effects and contraindications

AOD-9604 has been well-tolerated in published trials and clinical use. The most commonly reported side effect is mild local injection site reaction. Importantly, the peptide does not produce the joint discomfort, water retention, paresthesias, or insulin resistance often seen with growth hormone or strong GH secretagogues — this favorable side effect profile is the main reason for its continued clinical use despite modest efficacy.

Long-term safety data remains limited. We avoid use during pregnancy and breastfeeding (general principle for peptides without dedicated reproductive safety data) and in patients with active malignancy as a precaution.

What we don’t yet know

The most important unresolved question is whether subcutaneous administration produces meaningfully larger effects than the oral route used in the 2007 trial. Practitioner experience suggests yes, but rigorous trial data is absent. Optimal dosing, ideal cycle length, and the role of AOD-9604 in modern combination protocols (with GLP-1 agonists, with growth hormone secretagogues, with structured exercise) are all areas where the evidence base is largely empirical. As a peptide that has remained in clinical use for over two decades without major safety signals but also without major efficacy breakthroughs, AOD-9604 occupies a niche role rather than a foundational one in our metabolic toolkit.